Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their ... The U.S. regulator has cleared Enhertu as the first HER2-directed treatment for patients with HER2-low or ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...

chemotherapy with a median progression-free survival of more than one year Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu to an earlier HR-positive treatment setting and broadens the patient ...

The trial showed an ORR of 62.6% for Enhertu compared to 34.4% for chemotherapy in HER2-low and HER2-ultralow ... $175 million as a milestone payment to Daiichi Sankyo. Daiichi Sankyo recognizes ...

The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...

Daiichi Sankyo, added: “Enhertu continues to redefine the classification and treatment of HR-positive metastatic breast cancer with important new data across the spectrum of HER2 expression.” ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were in ... Enhertu just received US approval for indication expansion into HER2-low or HER2-ultralow chemo-naïve patients in January ...

We will now would like to start Daiichi Sankyo's Financial Results Briefing ... Fiscal year 2024 Q3 year-to-date sales grew led by HER2+ breast cancer second line treatment and chemotherapy ...